Nebulized budesonide vs. ipratropium as an add-on to salbutamol in preschool wheeze ‒ a randomized controlled trial
DOI:
https://doi.org/10.15584/ejcem.2026.3.11Keywords:
budesonide, child, ipratropium, preschool, salbutamol, wheezingAbstract
Introduction and aim. Acute wheeze is common cause of emergency visits and hospitalization in preschool children. This randomized controlled trial directly compared nebulized budesonide versus ipratropium bromide as add-on therapy to salbutamol in children aged 1–5 years with moderate-to-severe acute wheeze.
Material and methods. This hospital-based randomized controlled trial included 84 children equally assigned to two groups. Group A received nebulized budesonide with salbutamol, and Group B received nebulized ipratropium bromide with salbutamol. The co-primary outcomes were the change in Pediatric Respiratory Assessment Measure (PRAM) score from baseline to 60 minutes and the PRAM score trajectory during the first 60 minutes.
Results. Baseline PRAM scores were comparable between groups. Group A showed significantly lower PRAM scores at 20, 40, 60 minutes, with greater mean PRAM reduction at 60 minutes (p<0.05). Mean time to achieve PRAM≤4 was shorter in Group A. Group A children had a significantly shorter hospital stay.
Conclusion: Nebulized budesonide as an add-on to salbutamol was associated with greater short-term improvement in PRAM scores and shorter hospital stay than ipratropium bromide; larger multicenter studies are needed.
Downloads
References
Abood HA, Almusawi ZH, Mahdi AA, Hameed R. Effects of nebulized budesonide plus salbutamol and nebulized salbutamol monotherapy on mild to moderate acute exacerbation of asthma in children. J Pak Med Assoc. 2021;71:29-34.
Ducharme FM, Chalut D, Plotnick L, et al. The pediatric respiratory assessment measure: a valid clinical score for assessing acute asthma severity from toddlers to teenagers. J Pediatr. 2008;152(4):476-480. doi:10.1016/j.jpeds.2007.08.034
Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2023.
British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax. 2019;74(Suppl 3):1-214.
Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. Thorax. 2005;60:740-746. doi:10.1136/thx.2005.040444
Xu H, Tong L, Gao P, et al. Combination of ipratropium bromide and salbutamol in children and adolescents with asthma: a meta-analysis. PLoS One. 2021;16(2):e0237620. doi:10.1371/journal.pone.0237620
Chen AH, Chen RC, Zhan JY, et al. The efficacy of nebulized budesonide in acute moderate to severe exacerbations of asthma in children. Zhonghua Jie He He Hu Xi Za Zhi. 2012;35(4):269-274.
Milani GK, Rosário Filho NA, Riedi CA, Figueiredo BC. Nebulized budesonide to treat acute asthma in children. J Pediatr (Rio J). 2004;80(2):106-112.
Murphy KR, Hong JG, Wandalsen G, et al. Nebulized inhaled corticosteroids in asthma treatment in children 5 years or younger: a systematic review. J Allergy Clin Immunol Pract. 2020;8(6):1815-1827. doi:10.1016/j.jaip.2020.01.042
Cyril J, Baburaj S, Nair P, Kuruvilla T, Bobby C, Das L. Comparative study of nebulized budesonide with levosalbutamol versus ipratropium bromide with levosalbutamol in acute asthma in children. Int J Contemp Pediatr. 2020;8:65-70. doi:10.18203/2349-3291.ijcp20205507
Li CY, Liu Z. Effect of budesonide on hospitalization rates among children with acute asthma attending pediatric emergency department: a systematic review and meta-analysis. World J Pediatr. 2021;17(2):152-163. doi:10.1007/s12519-020-00403-y
Afshar AA, Rahmati M, Maleki A, Kamali K. Effectiveness of budesonide in the treatment of asthma attacks in children: a systematic review and meta-analysis. Prev Care Nurs Midwifery J. 2023;13(3):9-18.
Razi C, Cörüt N, Andıran N. Budesonide reduces hospital admission rates in preschool children with acute wheezing. Pediatr Pulmonol. 2017;52:720-728. doi:10.1002/ppul.23667
Akbaş ED, Razi C, Andıran N. Effects of using montelukast during acute wheezing attack in hospitalized preschool children on the discharge rate and the clinical asthma score. Pediatr Pulmonol. 2021;56:1931-1937. doi:10.1002/ppul.25394
Upham BD, Mollen CJ, Scarfone RJ, Seiden JA, Chew A, Zorc JJ. Nebulized budesonide added to standard pediatric emergency department treatment of acute asthma: a randomized, double-blind trial. Acad Emerg Med. 2011;18(7):665-673. doi:10.1111/j.1553-2712.2011.01114.x
Wyatt EL, Borland ML, Doyle SK, Geelhoed GC. Metered-dose inhaler ipratropium bromide in moderate acute asthma in children: a single-blinded randomized controlled trial. J Paediatr Child Health. 2015;51:1033-1039. doi:10.1111/jpc.12692
Chen A, Zeng G, Chen R, et al. Effects of nebulized high-dose budesonide on moderate-to-severe acute exacerbation of asthma in children: a randomized, double-blind, placebo-controlled study. Respirology. 2013;18:122-128. doi:10.1111/resp.12168
Alangari AA, Malhis N, Mubasher M, et al. Budesonide nebulization added to systemic prednisolone in the treatment of acute asthma in children: a double-blind, randomized, controlled trial. Chest. 2014;145(4):772-778. doi:10.1378/chest.13-2298
Kartininingsih L, Setiawati L. Comparison of clinical efficacy and safety between salbutamol-ipratropium bromide nebulization and salbutamol alone in children with asthmatic attack. Paediatr Indones. 2016;46(6):241-245. doi:10.14238/pi46.6.2006.241-5
Iramain R, Castro-Rodriguez JA, Jara A, et al. Salbutamol and ipratropium by inhaler is superior to nebulizer in children with severe acute asthma exacerbation: a randomized clinical trial. Pediatr Pulmonol. 2019;54:372-377. doi:10.1002/ppul.24244
Özdemir M. Efficacy of ipratropium bromide in moderate and severe asthma attack in children. Haydarpasa Numune Med J. 2019;59:358-366. doi:10.14744/hnhj.2019.99705
Joiya SJ, Khan MKA, Haq F, Ahmad ZP. Comparison of outcome of salbutamol alone and salbutamol in combination with ipratropium bromide in acute asthma in children. Prof Med J. 2020;27(6):1175-1181. doi:10.29309/TPMJ/2020.27.06.3218
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
